Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PRAME-targeted TCR-engineered iNKT cell therapy
- Development stage
- Preclinical
- Lead developer
- MiNK Therapeutics
- Modality
- CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, TCR-Engineered T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
PRAME-targeted TCR-engineered iNKT cell therapy (CF-033) is an allogeneic, off-the-shelf cell-based biologic therapy being developed by MiNK Therapeutics in collaboration with the C-Further international pediatric oncology consortium. The therapy consists of donor-derived invariant natural killer T (iNKT) cells that have been genetically engineered to express a T cell receptor (TCR) specific for the tumor-associated antigen PRAME (Preferentially Expressed Antigen in Melanoma). This approach leverages the unique properties of iNKT cells, which possess both innate and adaptive immune functions and can home to tumor tissues without the requirement for HLA matching. CF-033 is designed to treat a variety of PRAME-expressing malignancies, including pediatric sarcomas, acute myeloid leukemia, and medulloblastoma, as well as adult solid tumors such as non-small cell lung cancer (NSCLC), ovarian cancer, and melanoma. The program is currently in preclinical development, with funding secured for IND-enabling studies as of early 2026.
- Other names
- PRAME-targeted TCR-engineered invariant natural killer T cell therapy
02
Targets
PRAME (Preferentially expressed antigen in melanoma)
Beyond the preview
Go deeper on PRAME-targeted TCR-engineered iNKT cell therapy.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PRAME-targeted TCR-engineered iNKT cell therapy.